Wave Life Sciences Ltd (WVE) — Cash Flow-to-Debt Ratio
Wave Life Sciences Ltd (WVE) has a Cash Flow-to-Debt Ratio of -0.83x as of March 2026, meaning its operating cash flow of $-59.55 Million could theoretically repay -1% of its total liabilities ($71.81 Million) in one year. Explore Wave Life Sciences Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wave Life Sciences Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Wave Life Sciences Ltd across 13 annual periods. Also explore how large is Wave Life Sciences Ltd's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Wave Life Sciences Ltd (2013–2025)
Year-by-year debt coverage analysis for Wave Life Sciences Ltd. For market capitalisation and broader financial context, see WVE market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.67x | $-187.49 Million | $112.27 Million | ▼ -57.8% |
| 2024 | -1.06x | $-151.03 Million | $142.69 Million | ▼ -1181.8% |
| 2023 | -0.08x | $-19.43 Million | $235.32 Million | ▲ +87.6% |
| 2022 | -0.67x | $-127.78 Million | $191.48 Million | ▼ -30.9% |
| 2021 | -0.51x | $-88.99 Million | $174.51 Million | ▲ +17.1% |
| 2020 | -0.62x | $-115.98 Million | $188.59 Million | ▲ +30.5% |
| 2019 | -0.89x | $-188.23 Million | $212.64 Million | ▼ -761.9% |
| 2018 | -0.10x | $-22.86 Million | $222.59 Million | ▲ +94.8% |
| 2017 | -1.99x | $-83.67 Million | $42.03 Million | ▼ -87.1% |
| 2016 | -1.06x | $-31.87 Million | $29.95 Million | ▼ -1.4% |
| 2015 | -1.05x | $-12.53 Million | $11.93 Million | ▲ +78.4% |
| 2014 | -4.86x | $-4.43 Million | $911.00K | ▼ -1279.8% |
| 2013 | -0.35x | $-3.55 Million | $10.09 Million | — |